Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M101233200 on April 17, 2001

J. Biol. Chem., Vol. 276, Issue 27, 25279-25286, July 6, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/27/25279    most recent
M101233200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.
Right arrow Articles by Wollheim, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.
Right arrow Articles by Wollheim, C. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pdx1 Level Defines Pancreatic Gene Expression Pattern and Cell Lineage Differentiation*

Haiyan WangDagger §, Pierre MaechlerDagger , Beate Ritz-Laser, Kerstin A. HagenfeldtDagger , Hisamitsu IshiharaDagger , Jacques Philippe, and Claes B. WollheimDagger §

From the Dagger  Division of Clinical Biochemistry and the  Diabetes Unit, Department of Internal Medicine, Geneva University Medical Center, CH-1211 Geneva 4, Switzerland

Received for publication, February 8, 2001, and in revised form, March 21, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The absence of Pdx1 and the expression of brain-4 distinguish alpha -cells from other pancreatic endocrine cell lineages. To define the transcription factor responsible for pancreatic cell differentiation, we employed the reverse tetracycline-dependent transactivator system in INS-I cell-derived subclones INSralpha beta and INSrbeta to achieve tightly controlled and conditional expression of wild type Pdx1 or its dominant-negative mutant, as well as brain-4. INSralpha beta cells express not only insulin but also glucagon and brain-4, while INSrbeta cells express only insulin. Overexpression of Pdx1 eliminated glucagon mRNA and protein in INSralpha beta cells and promoted the expression of beta -cell-specific genes in INSrbeta cells. Induction of dominant-negative Pdx1 in INSralpha beta cells resulted in differentiation of insulin-producing beta -cells into glucagon-containing alpha -cells without altering brain4 expression. Loss of Pdx1 function alone in INSrbeta cells, which do not express endogenous brain-4 and glucagon, was also sufficient to abolish the expression of genes restricted to beta -cells and to cause alpha -cell differentiation. In contrast, induction of brain-4 in INSrbeta cells initiated detectable expression of glucagon but did not affect beta -cell-specific gene expression. In conclusion, Pdx1 confers the expression of pancreatic beta -cell-specific genes, such as genes encoding insulin, islet amyloid polypeptide, Glut2, and Nkx6.1. Pdx1 defines pancreatic cell lineage differentiation. Loss of Pdx1 function rather than expression of brain4 is a prerequisite for alpha -cell differentiation.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The pancreatic islets of Langerhans are composed of four different endocrine cell types: glucagon- (alpha ), insulin- (beta ), somatostatin- (delta ), and pancreatic polypeptide-producing cells (1). These four endocrine cell lineages are differentiated from a common neurogenin3-expressing precursor (2-6). Targeted disruption of mouse genes encoding various transcription factors has demonstrated their importance in the control of islet cell development and differentiation. The homozygous deletion of the Pdx1/Ipf1/Idx1/Stf1 gene in mice (7, 8) and in a patient (9) causes pancreas agenesis. In neuroD-null mice, the endocrine (alpha , beta , and delta ) cell mass is markedly reduced (10). In Isl1-deficient mice, the dorsal pancreatic mesenchyme and four hormone-producing endocrine cell lineages are deleted (11). Homozygous disruption of the Nkx2.2 gene in mice results in reduced alpha  and pancreatic polypeptide cell mass as well as defective beta -cell differentiation (12). Pax6 is indispensable for alpha -cell development (13, 14), whereas homozygous Pax4-null mice lack beta - and delta -cells (15). Nkx6.1 is required for mature beta -cell differentiation and beta -cell neogenesis during the secondary transition (16).

The beta -cell-specific inactivation of the Pdx1 gene in mice has revealed that Pdx1 is required for maintaining the beta -cell phenotype by positively regulating insulin expression and by repressing glucagon expression (17). Furthermore, brain4 has been suggested to confer the pancreatic alpha -cell specificity (18). The absence of Pdx1 and the expression of brain4 are characteristics of the mature islet alpha -cell lineage (5, 6, 8, 18-20). Nkx6.1 is exclusively expressed in islet beta -cells after embryonic day 13 (17, 21, 22) and is required for mature beta -cell differentiation (16). Pax4, which is expressed only transiently in the fetal pancreas and functions as a transcriptional repressor of the glucagon promoter, plays a significant role in the development and differentiation of islet beta /delta cells (15, 23-25). It has been demonstrated that Pdx1 binds to the promoters of the Nkx6.1 and Pax4, and Pdx1 is also necessary for Nkx6.1 expression (17, 25, 26). However, the correlation of Pdx1 function with the expression of brain4 and Pax4 in the transcriptional hierarchy has not been well defined.

The pluripotent property of islet tumor cells has been described and used as a model to study islet cell differentiation and to identify islet cell-specific transcription factors (18, 20, 21, 27-29). INS-1 cells, which express endogenous pancreatic transcription factors Pdx1, neuroD, Isl1, Pax4, Pax6, Nkx2.2, Nkx6.1, HNF1alpha , and HNF4alpha (30) and display differentiation plasticity, would be suitable for elucidating the function of transcription factors in islet cell differentiation. The present study was designed to define the role of Pdx1 and brain4 in the regulation of pancreatic cell lineage differentiation using INS-1-derived stable cell lines expressing Pdx1, its dominant-negative mutant (DN1-Pdx1), or brain4 under the control of the reverse tetracycline-dependent transactivator (rtTA) (31). The established INS-1 subclones would also allow us to pinpoint the Pdx1-specific downstream target genes.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of the Rat Brain4 cDNA, Construction of Plasmids, and Generation of Stable Cell Lines-- The rat insulinoma INS-1 cell line-derived stable clones were cultured in RPMI 1640 in 11.2 mM glucose (30), unless otherwise indicated. The first-step stable clones INSralpha beta and INSrbeta , which express the reverse tetracycline-dependent transactivator, were reported previously as INS-r3 and INS-r9, respectively (32). Plasmids used in the secondary stable transfection were constructed by subcloning the cDNAs encoding the mouse Pdx1 (kindly supplied by Dr. H. Edlund, Umea, Sweden), its dominant-negative mutant (DN-Pdx1), and the rat brain4 into the expression vector PUHD10-3 (a kind gift from Dr. H. Bujard). DN-Pdx1 (truncated mutation lacking the first 79 amino acids) was PCR-amplified from Pdx1 using the following primers: 5'-gcaggatccgctcacctccaccaccaccttccagct-3' and 5'-ggcagatctggccattagcttggcatcagaagc-3'. The PCR fragment was subcloned into modified pcDNA3.1myc (Invitrogene) and sequenced. The rat brain4 cDNA was cloned by reverse transcription-PCR using RNA from freshly isolated rat islets and the following primers: 5'-gaccatggccacagctgcctc-3' and 5'-tgcagcgggccacctccttg-3'. The PCR product was inserted into the pGEM-T Easy Vector (Promega/Catalys) according to the manufacturer's protocol and sequenced. The stable transfection and the clone selection and screening procedures were described previously (32).

Immunoblot and Immunofluorescence-- Immunoblotting procedures were performed as described previously using enhanced chemiluminescence (Pierce) for detection (30). The dilution for antibody against Pdx1 C terminus (a kind gift from Dr. H. Edlund) was 1:5,000.

For immunofluorescence cells were grown on polyornithine-treated glass coverslips for 1 day prior to 4 days of treatment with 500 ng/ml doxycycline. The cells were then washed, fixed in 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline containing 1% bovine serum albumin. The preparation was then blocked with phosphate-buffered saline-bovine serum albumin before incubating with the first antibodies mouse monoclonal anti-human insulin (1:1,000 dilution; from Sigma) and rabbit polyclonal anti-porcine glucagon (1:2,500 dilution) (33), followed by the second antibody labeling. The resultant immunofluorescence was viewed using a Zeiss laser scan confocal 410 microscope (Zurich, Switzerland).

Nuclear Extract Preparation and Electrophoretic Mobility Shift Assay (EMSA)-- Nuclear extracts from INS-1 cells grown in culture medium with or without 500 ng/ml doxycycline for 24 h and from BHK-21 cells transfected with various expression plasmids were prepared according to Schreiber et al. (34). The following double-stranded oligonucleotides were used as probes: the rat insulin I FLAT element 5'-GATCTTGTTAATAATCTAATTACC-3' (35, 36) and the rat glucagon G1 element (37). EMSA procedures including conditions for probe labeling, binding reactions, unlabeled probe competition, and antibody supershift were performed as previously reported (37). Polyclonal antibodies raised against Pdx1 and Pax-6 were generously provided by H. Edlund and S. Saule, respectively.

Cell Extract Fractionation-- Cells in 10-cm diameter dishes were cultured with or without 500 ng/ml doxycycline for 24 h at 2.5, 6, 12, and 24 mM glucose. After washing twice with ice-cold phosphate-buffered saline, the cells were suspended and allowed to swell for 15 min at 4 °C in 400 µl of hypotonic buffer composed of 20 mM Tris (pH 7.4), 5 mM EDTA, 2 mM dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluoride. After 3 cycles of freeze-thaw, the cytosolic proteins (supernatant) were separated from the nuclear fraction (pellet) by centrifugation. The nuclear proteins were further isolated from the pellet according to Schreiber et al. (34).

Total RNA Isolation and Northern Blotting-- Cells in 10-cm diameter dishes were cultured in normal (11.2 mM) glucose medium with or without 500 ng/ml doxycycline for the indicated times, followed by an additional 8 h in culture medium with 2.5, 6, 12, and 24 mM glucose. Total RNA was extracted and blotted to nylon membranes as described previously (32). The membrane was prehybridized and then hybridized to 32P-labeled random primer cDNA probes as previously described (38). To ensure equal RNA loading and even transfer, all membranes were stripped and rehybridized with "house-keeping gene" probes such as beta -actin or cyclophilin. cDNA fragments used as probes for glucokinase, Glut2, insulin, Pdx1, and brain4 mRNA detection were digested from corresponding plasmids. cDNA probes for rat islet amyloid polypeptide (IAPP), somatostatin, glucagon, Nkx6.1, Nkx2.2, Pax4, Pax6, Isl1, and beta 2/NeuroD were prepared by reverse transcription-PCR and confirmed by sequencing.

Transient Transfection and Luciferase Assay-- Transient transfection experiments and luciferase reporter enzyme assays were carried out as previously reported (39). To overexpress transcription factors for EMSA, non-islet Syrian baby hamster kidney (BHK-21) cells were transfected by the calcium phosphate precipitation using 10 µg of expression plasmids encoding quail Pax6 (S. Saule, Institut Curie, Paris, France), hamster Cdx-2/3 (M. S. German, University of California, San Francisco, CA), and mouse Pdx1 or DN-Pdx1.

Cellular Insulin and Glucagon Content-- Cells in 24-well dishes were cultured with or without 500 ng/ml doxycycline for 4 days. The content of insulin and glucagon was determined after extraction with acid ethanol or 0.2% Tween 20 in phosphate-buffered saline containing 6 milliunits/ml aprotinin, respectively, following the procedures of Wang et al. (39). Insulin was detected by radioimmunoassay using rat insulin as standard (39), and glucagon was measured with a glucagon assay kit (Linco, St. Charles, MO).

Insulin Secretion-- Cells in 24-well dishes were cultured for 2 days in INS-1 medium followed by 5 h of equilibration in 2.5 mM medium. Insulin secretion was measured in the presence of 2.5, 6, 12, or 24 mM glucose using Krebs-Ringer bicarbonate HEPES buffer as previously described (39).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Characterization of INS-1-derived Subclones Expressing the rtTA and Establishment of Secondary Stable Lines Overexpressing Pdx1, DN-Pdx1, or Brain4-- The rat insulinoma INS-1 cells were used as the parental line for stable transfection of an expression plasmid encoding the rtTA (31, 32). A clone termed INSrbeta , which maintains the INS-1 beta -cell phenotype, and another clone called INSralpha beta , which represents a hybrid of alpha - and beta -cells, were used for the present study. As shown in Fig. 1, INS-rbeta and INS-1 cells express predominantly the beta -cell-specific markers insulin and IAPP. In contrast, INSralpha beta cells express not only insulin and IAPP but also glucagon and brain4 (Fig. 1). Somatostatin mRNA was abundantly expressed in freshly isolated islets but not detected in parental INS-1 cells or derived clones (Fig. 1). Pdx1 mRNA was present in both INSrbeta and INSralpha beta lines (Fig. 1).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of INS-1-derived INSrbeta and INSralpha beta subclones by Northern blot analysis of mRNA expression. Total RNAs were extracted from freshly isolated rat islets, parental INS-1 cells, and rtTA-expressing subclones INSrbeta and INSralpha beta . 20-µg RNA samples were analyzed by hybridizing with the indicated 32P-labeled cDNA probes.

To study whether the production of glucagon in INSralpha beta cells is correlated with the expression of brain4, we generated an INSrbeta -derived stable cell line expressing brain4 in a doxycycline-inducible manner. The cDNA encoding brain4 was obtained by reverse transcription-PCR using RNA from freshly isolated rat islets, cloned into pGEM-T vector, and sequenced. To delineate the Pdx1-specific target genes and the Pdx1-regulated islet cell lineage differentiation, we also established both INSrbeta - and INSralpha beta -derived stable clones expressing Pdx1 or DN-Pdx1 under the control of rtTA. DN-Pdx1 represents the epitope Myc-tagged truncated Pdx1 mutant protein lacking the N-terminal transactivation domain (the first 79 amino acids) (40). The clones, named rbeta -brain4-119, rbeta -Pdx1-6, rbeta -DN-Pdx1-28, ralpha beta -Pdx1-21, and ralpha beta -DN-Pdx1-59, which expressed the transgenes at the highest level after induction and showed only background expression under non-induced conditions, were selected for the present study.

Both Pdx1 and DN-Pdx1 Proteins Translocated from the Cytoplasm to the Nucleus in a Glucose-dependent Manner but Did Not Change Molecular Mass-- It has been reported that glucose stimulates translocation of Pdx1 from the cytoplasm or nuclear periphery to the nucleus in human islets and MIN6 cells (41-43). Macfarlane et al. (41) also demonstrated that the Pdx1 translocation is concomitant with a shift in molecular mass from 31 to 46 kDa, whereas Rafiq et al. (42) reported no such change. We investigated the intracellular location of both endogenous Pdx1 and induced Pdx1 using cytoplasmic and nuclear fractions prepared from ralpha beta -Pdx1-21 cells incubated in 2.5, 6, 12, and 24 mM glucose, respectively, for 24 h (Fig. 2A). The majority of Pdx1 protein was present in the cytosolic fraction when ralpha beta -Pdx1-21 cells were maintained at 2.5 mM extracellular glucose concentration; however, in 6 mM glucose, Pdx1 predominantly translocated to the nuclear fraction (Fig. 2A). Similar results were obtained using the rbeta -Pdx1-6 line (data not shown). The 31-kDa form of Pdx1 described by Macfarlane et al. (41) was not detected by Western blotting of the cytoplasmic fraction (Fig. 2A) or whole cell extracts (data not shown) from the INS-1-derived clones. Nevertheless, the endogenous Pdx1 protein in Min6-m9 cells (44) also translocated from the cytoplasm to the nucleus in a glucose-dependent manner but did not change molecular mass (Fig. 2B). However, there is a clear difference in glucose responsiveness in INS-1-derived cells compared with MIN6-m9 cells, because Pdx1 translocation was maximally stimulated at glucose concentrations between 2.5 and 6 mM in INS-1-derived clones (Fig. 2A), whereas glucose-regulated Pdx1 translocation occurred over the full range from 2.5 to 24 mM glucose in MIN6-m9 cells (Fig. 2B). The induced DN-Pdx1 mutant protein lacking the N-terminal transactivation domain translocated in a way similar to endogenous Pdx1 in both ralpha beta -DN-Pdx1-59 (Fig. 2C) and rbeta -DN-Pdx1-28 (Fig. 2D) cells, in agreement with the identification of the nuclear localization signal in the Pdx1 homeodomain (45).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   Cellular translocation of Pdx1 and DN-Pdx1 proteins in response to incremental extracellular glucose concentrations. Nuclear extracts and cytosolic proteins were prepared from ralpha beta -Pdx1-21 (A), MIN6-m9 (B), ralpha beta -DN-Pdx1-59 (C), and rbeta -DN-Pdx1-28 (D) cells cultured with or without 500 ng/ml doxycycline for 24 h at the indicated glucose concentrations. 10 µg of protein from the nuclear extracts or 100 µg of protein from the cytosolic fraction were resolved via 9% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and immunoblotted with an antibody against the Pdx1 C terminus. NE, nuclear extracts from cells in 11.2 mM glucose; kD, kilodaltons.

It is noteworthy that the glucose responsiveness, in terms of both Pdx1 translocation and insulin secretion in INSralpha beta -derived cells, was equivalent to that in INSrbeta -derived cells (Fig. 2, A, C, and D and Table I). The right shift of the glucose-induced Pdx1 translocation in MIN6-m9 cells (Fig. 2B) corresponds to the right shift of the glucose-stimulated insulin secretion in these cells (44) relative to INS-1-derived cells (Fig. 2, A, C, and D and Table I). Thus, half-maximal insulin secretion in MIN6-m9 cells was observed at 15 mM glucose (44), whereas the value is 6 mM in the INS-1-derived clones (Table I). Whether or not there is a direct correlation between the glucose-induced Pdx1 translocation and the glucose-stimulated insulin secretion remains to be established.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Glucose-stimulated insulin secretion in INSralpha beta - and INSrbeta -derived clones
The amount of insulin released over 30 min from INSralpha beta -derived ralpha beta -DN-Pdx1-59 clone and INSrbeta -derived rbeta -Pdx1-6 clone is presented as percent of insulin content. Data from six independent experiments are shown as means ± S.E.

Induction of Pdx1 Eliminates Glucagon Expression in INSralpha beta Cells and Promotes beta -Cell-specific Gene Expression in INSrbeta Cells-- Quantitative Northern blotting was employed to study the impact of induction of Pdx1 on the expression of INS-1 mRNAs at extracellular glucose concentrations of 2.5, 6, 12, and 24 mM. As demonstrated in Fig. 3A, glucagon mRNA expression in INSralpha beta cells was no longer detectable after induction of Pdx1 for 48 h, whereas brain4 mRNA remained constant. Overexpression of Pdx1 in ralpha beta -Pdx1-21 cells slightly raised the mRNA level of Nkx6.1 but had no significant effect on the mRNA expression of Nkx2.2, Pax4, Pax6, Isl1, and beta 2/NeuroD (Fig. 1A). We also performed EMSA experiments with a probe corresponding to the rat insulin I FLAT element, which contains the Pdx1-binding site (35, 36). Using nuclear extracts from ralpha beta -Pdx1-21 cells cultured with or without 500 ng/ml doxycycline for 24 h, we found that induction of Pdx1 resulted in a dramatic increase (>20-fold) in its binding activity to the rat insulin promoter (data not shown). Unexpectedly, we did not see a concomitant rise in the mRNA levels of insulin or IAPP (Fig. 3A). Interestingly, the insulin content in ralpha beta -Pdx1-21 cells was increased by more than 2-fold (-Dox, 33.65 ± 1.37 ng/mg or protein versus +Dox, 74.55 ± 17.23 ng/mg of protein; p < 0.005) after 4 days induction of Pdx1, despite the fact that the insulin mRNA was reduced by 32.6% under the same condition. In contrast, the glucagon content in ralpha beta -Pdx1-21 cells dropped by 94% (-Dox, 8.09 ± 1.51 ng/mg of protein versus +Dox, 0.48 ± 0.11 ng/mg of protein; p < 0.001) after induction of Pdx1 for 4 days. Consistently, the immunofluorescence double staining of ralpha beta -Pdx1-21 cells showed that the glucagon expression was no longer detectable, whereas the insulin level was concomitantly increased after doxycycline induction for 4 days (Fig. 3B).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   Induction of Pdx1 eliminates endogenous glucagon expression in ralpha beta -Pdx1-21 cells and promotes beta -cell-specific gene expression in rbeta -Pdx1-6 cells. A, Northern blot analysis of gene expression in ralpha beta -Pdx1-21 cells induced with 500 ng/ml doxycycline and cultured first in normal (11.2 mM) glucose medium for 24 or 48 h and then incubated further for 8 h at the indicated glucose concentrations. 20 µg of total RNA samples were analyzed by hybridizing with indicated cDNA probes. B, double immunofluorescence staining with anti-insulin serum (green) and anti-glucagon serum (red) in ralpha beta -Pdx1-21 cells cultured in the absence (-Dox) or the presence (+Dox) of 500 ng/ml doxycycline for 4 days. C, Northern blotting quantification of gene expression in rbeta -Pdx1-6 cells induced with indicated concentrations of doxycycline and cultured in normal (11.2 mM) glucose medium for 48 h. Total RNA samples extracted from two independent experiments were blotted in parallel to demonstrate the consistency of the data. 20 µg of RNA per lane were loaded and analyzed by hybridizing with the indicated cDNA probes. GK, glucokinase.

As shown in Fig. 3C, the graded overexpression of Pdx1 in rbeta -Pdx1-6 cells caused a stepwise increase in the expression of Nkx6.1 mRNA. The expression of another beta -cell-specific marker, Glut2, was also slightly increased by induction of Pdx1 (Fig. 3C). Overexpression of Pdx1 alone is not sufficient to raise the endogenous insulin and IAPP mRNA levels (Fig. 3C). However, overexpression of Pdx1 may facilitate the biosynthesis of insulin or the formation (or maturation) of insulin granules, because doxycycline treatment for 4 days also significantly increased the insulin content in rbeta -Pdx1-6 cells without altering insulin mRNA expression.2

Loss of Pdx1 Function Converts INSralpha beta and INSrbeta Cells into Glucagon-predominant alpha -Cells Independent of Brain4 Expression-- We predicted that DN-Pdx1, which lacks the transactivation domain but preserves an intact DNA-binding domain (40), would exert its dominant-negative function by competing with endogenous Pdx1 for binding to the cognate site in the rat insulin promoter. Indeed, our EMSA experiments using nuclear extracts from ralpha beta -DN-Pdx1-59 cells showed that the binding activity of endogenous Pdx1 to the rat insulin I FLAT element was abolished over 90% after 24 h of induction of DN-Pdx1 (data not shown). The expression of beta -cell-specific genes encoding insulin, IAPP, Glut2, and Nkx6.1 was drastically reduced but not completely eliminated after treatment of ralpha beta -DN-Pdx1-59 cells with doxycycline for 4 days (Fig. 4A). Concomitantly, the glucagon transcript level in these cells increased 5- and 10-fold after induction of DN-Pdx1 for 2 and 4 days, respectively, whereas brain4 mRNA expression was not altered (Fig. 4A). Similarly, immunofluorescence confocal microscopy studies in ralpha beta -DN-Pdx1-59 cells showed that the insulin-staining cells were lost by 90%, and the glucagon-staining cells accounted for over 90% of the whole cell population after treatment with doxycycline for 4 days (Fig. 4B). Accordingly, the insulin content in these cells decreased by 72% (48.15 ± 8.81 versus 13.68 ± 1.56 ng/mg of protein; p < 0.001), whereas the glucagon content increased over 2-fold (35.77 + 7.69 versus 75.07 + 6.12 ng/mg of protein; p < 0.001). Induction of DN-Pdx1 had no significant effect on the mRNA expression of beta 2/NeuroD, Pax4, Pax6, Nkx2.2, and Isl-1 (Fig. 4A), suggesting that these pancreatic transcription factors are not Pdx1-specific target genes.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 4.   Induction of DN-Pdx1 in ralpha beta -DN-Pdx1-59 and rbeta -DN-Pdx1-28 cells converted the insulin-producing beta -cell lineage into the glucagon predominant alpha -cell phenotype. A, quantitative evaluation by Northern blotting of the gene expression profile in ralpha beta -DN-Pdx1-59 cells induced with 500 ng/ml doxycycline and cultured first in normal (11.2 mM) glucose medium for 2 or 4 days and then incubated further for 8 h at the indicated glucose concentrations. 20 µg of total RNA samples were analyzed by hybridizing with indicated cDNA probes. B, double immunofluorescence staining with anti-insulin serum (green) and anti-glucagon serum (red) in ralpha beta -DN-Pdx1-59 cells cultured with or without 500 ng/ml doxycycline for 4 days. C, Northern blot analysis of gene expression patterns in rbeta -DN-Pdx1-28 cells induced with 500 ng/ml doxycycline and cultured first in normal (11.2 mM) glucose medium for 4 or 7 days and then incubated further for 8 h at the indicated glucose concentrations. 20 µg of total RNA samples were analyzed by hybridizing with the indicated cDNA probes. GK, glucokinase; WT, wild type.

We also performed quantitative Northern blot analysis to investigate the consequences of DN-Pdx1 induction on the gene expression patterns of rbeta -DN-Pdx1-28 cells that do not express detectable endogenous brain4. As shown in Fig. 4C, the expression of islet beta -cell-specific markers, insulin, IAPP, Glut2, and Nkx6.1 in rbeta -DN-Pdx1-28 cells was dramatically decreased in a time-dependent manner (Fig. 4C). In contrast, glucagon mRNA expression in rbeta -DN-Pdx1-28 cells (Fig. 4C) rose from an undetectable background to a level comparable with that of fully induced ralpha beta -DN-Pdx1-59 cells (Fig. 4A), whereas brain4 mRNA remained undetectable (data not shown) after induction of DN-Pdx1. These results demonstrate that dominant-negative suppression of Pdx1 function alone is sufficient to differentiate the insulin-predominant beta -cell lineage to the glucagon-predominant alpha -cell phenotype. The brain4 expression is not required for this effect, although there is a time delay in glucagon gene expression comparing rbeta -DN-Pdx1-28 (Fig. 4C) with ralpha beta -DN-Pdx1-59 cells (Fig. 4A).

Although it has been proposed that Pdx1 regulates the human glucokinase promoter activity (46), we found that the endogenous rat glucokinase mRNA expression was unresponsive to Pdx1 function in rbeta -Pdx1-6 (Fig. 3C), rbeta -DN-Pdx1-28 (Fig. 4C), ralpha beta -Pdx1-21 (Fig. 3A), and ralpha beta -DN-Pdx1-59 (Fig. 4A) cells.

Induction of Brain4 Is Sufficient for Initiating a Detectable Level of Glucagon Expression in INS-rbeta Cells but Not Mature alpha -Cell Differentiation-- To investigate whether loss of Pdx1 function is necessary for alpha -cell differentiation, we examined the gene expression patterns in rbeta -brain4-119 cells using Northern blot analysis. After induction of brain4 at an extremely high level for 4 days, glucagon mRNA expression was initiated to a detectable level (Fig. 5) that is, however, 10-20-fold lower compared with that of rbeta -DN-Pdx1-28 (Fig. 4C) and ralpha beta -DN-Pdx1-59 (Fig. 4A) cells under similar conditions. Unlike induction of DN-Pdx1, however, forced expression of brain4 did not alter the mRNA levels of islet beta -cell-specific genes encoding insulin, IAPP, Nkx6.1, and Glut2 (Fig. 5). Pdx1 is not the up-stream transcriptional regulator of brain4 (Figs. 3A and 4A); conversely induction of brain4 did not affect the Pdx1 expression either (Fig. 5).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 5.   Induction of brain4 in the rbeta -brain4-119 clone triggered only a detectable level of glucagon expression but did not suppress the beta -cell-specific gene expression. Northern blot analysis of gene expression in rbeta -brain4-119 cells induced with 500 ng/ml doxycycline and cultured first in normal (11.2 mM) glucose medium for 4 days and then incubated further for 8 h at the indicated glucose concentrations. 20 µg of total RNA samples were analyzed by hybridizing with the indicated cDNA probes. GK, glucokinase.

Pdx1 Represses the Glucagon Promoter Activity, Binds the G1 Element, but Does Not Compete with Pax6 for DNA Binding-- To investigate whether Pdx1 suppresses the glucagon promoter activity, we performed transient transfection experiments in ralpha beta -Pdx1-21 and ralpha beta -DN-Pdx1-59 lines using a reporter plasmid consisting of the firefly luciferase gene driven by the rat glucagon promoter (-350GlucagonLuc). As expected, induction of Pdx1 for 24 h caused a 65% reduction (-Dox, 5.13 ± 1.68 light units/mg of protein versus +Dox, 1.81 ± 0.4 light units/mg of protein; p < 0.005; six independent experiments) in the luciferase reporter enzyme activity in ralpha beta -Pdx1-21 cells transfected with -350GlucagonLuc. Consistently, induction of DN-Pdx1 for 24 h in ralpha beta -DN-Pdx1-59 cells resulted in a 5.8-fold increase (-Dox, 3.66 ± 1.07 light units/mg of protein versus +Dox, 21.4 ± 4.98 light units/mg of protein; p < 0.001; six separate experiments) in the glucagon promoter activity.

To explore the possible mechanism underlying the repressive function of Pdx1 on glucagon gene promoter activity, we performed EMSA experiments using nuclear extracts from ralpha beta -Pdx1-21 and ralpha beta -DN-Pdx1-59 cells and the G1 element of the rat glucagon promoter that confers alpha  cell specificity (37). As shown in Fig. 6A, Pdx1 overexpressed in ralpha beta -Pdx1-21 cells formed a complex on G1 that migrated similarly to the paired homeodomain protein Pax-6, a major G1-binding factor. Similarly, DN-Pdx1 from doxycycline-induced ralpha beta -DN-Pdx1-59 cells interacted with the G1 element, and anti-Pdx1 antibodies specifically recognized both Pdx1 protein complexes (Fig. 6A). To assess the affinity of DN-Pdx1 and Pax-6 for G1, we performed EMSA competition experiments. When BHK-21 nuclear extracts containing Pax-6 were mixed with DN-Pdx-1-containing extracts, Pdx1 formed a weaker complex on G1-56 as compared with the individual binding reaction (Fig. 6B). Furthermore, a 10 times greater excess of cold G1-56 was required to compete for DN-Pdx1 than for Pax-6, indicating a better affinity of Pax-6 for G1 as compared with DN-Pdx1. It has previously been shown that Pdx1 has a lower affinity for G1 when compared with Pax-6 but an affinity similar to that of Cdx-2/3, a homeodomain protein interacting synergistically with Pax-6 on G1.3 Similarly, Cdx-2/3 and DN-Pdx1 displayed comparable affinity for G1 (Fig. 6C). However, because Pdx1 and DN-Pdx1 had opposite effects on glucagon promoter activity, it is unlikely that Pdx1 exerts transcriptional repression through its binding to the G1 element. Its ability to interact with other pancreatic transcription factors at the protein level could be an alternative explanation, because we found that Pdx1 suppressed the transactivation of Pax6 through protein-protein interaction independent of DNA binding.3


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   Pdx1 and DN-Pdx1 bind to the glucagon gene promoter element G1. A, EMSA using nuclear extracts from ralpha beta -Pdx1-21 and ralpha beta -DN-Pdx1-59 cells incubated for 24 h in the absence or presence of 500 ng/ml doxycycline. Both Pdx1 and DN-Pdx1 were able to bind G1. Px6 and Px1 indicate the addition of anti-Pax-6 and anti-Pdx1 antibodies, respectively. B and C, competition experiments analyzing the relative affinity of DN-Pdx1 and Pax-6 or Cdx-2/3 for the G1 element. Protein-DNA complexes formed with nuclear extracts from BHK-21 cells overexpressing DN-Pdx1, Pax-6, or Cdx-2/3 were competed for by the indicated molar excess of cold G1-56 oligonucleotides.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Establishment of an in Vitro Model of Islet Cell Lineage Differentiation-- Overexpression of a transcription factor, CCAAT/enhancer-binding protein beta , in a pancreatic tumor cell line has recently been demonstrated to provoke the transdifferentiation toward the hepatocyte phenotype (47). In fact, the differentiation potential and the multihormonal phenotype of islet tumor cells have been known for a long time (27, 28). We found that rat insulinoma INS-1 cells also display high plasticity of differentiation, and we could actually detect by reverse transcription-PCR (data not shown) the mRNAs of four islet hormones but not the exocrine marker, p48 (48). In addition, we demonstrated that INS-1 cells express multiple endogenous pancreatic transcription factors including Pdx1, Nkx6.1, Nkx2.2, Pax4, Pax6, beta 2/NeuroD, and Isl1 (30), which are important for regulation of islet cell differentiation and gene expression (49). Therefore, the INS-1 cells represent neither pancreatic precursor cells nor mature differentiated mono-hormone-producing islet cells. We defined, by quantitative Northern blot analysis, two rtTA-expressing INS-1-derived subclones termed INSrbeta , expressing predominantly insulin, and INSralpha beta , producing both insulin and glucagon. However, we did not obtain any clone showing predominantly the alpha -cell, delta -cell, or pancreatic polypeptide cell phenotype. We implemented the doxycycline-inducible system (Tet-on) (31) in INSrbeta and INSralpha beta lines to study the role of Pdx1 and brain4 in the regulation of islet cell lineage differentiation and gene expression. Using the inducible cell line rather than two distinct stable clones enabled us to tightly control the level of transgenes and also to precisely quantify the gene expression patterns under induced and non-induced conditions. It is important to note that doxycycline itself, or the induction of an irrelevant protein, had no effect on mRNA expression, insulin secretion, and insulin content in INS-1 cells (30, 32). We also demonstrated the differentiation plasticity of these cell lines by immunofluorescence double staining with antibodies against insulin and glucagon.

Glucose Regulates the Cellular Translocation of Pdx1 Protein without Altering Its Molecular Mass-- The present study supports the previous reports that glucose stimulates translocation of Pdx1 from the cytoplasm or nuclear periphery to the nuclei (41, 42). In addition, we found that the majority of Pdx1 protein is located in the nucleus at physiological concentrations of glucose (6 mM). During starvation associated with hypoglycemia, Pdx1 would be transported out of the nuclei, which may prevent the beta -cell from producing excessive insulin. Although Macfarlane et al. (41) reported a shift in the molecular mass of Pdx1 (from 31 to 46 kDa) concomitant with the glucose-stimulated Pdx1 translocation, our Western blotting data demonstrated that Pdx1 protein migrated at a constant molecular mass of 46 kDa irrespective of the glucose concentration. Our results are in agreement with another study by Rafiq et al. (42). The nuclear localization signal of Pdx1 has been identified as part of the homeodomain (45). This explains why the translocation of DN-Pdx1 lacking the N-terminal transactivation domain resembled that of wild type Pdx1.

Pdx1 Paradox-- Pdx1 exerts paradoxical effects on insulin mRNA expression and insulin promoter activity in insulin-producing cells and non-beta -cells (40, 50-56). The ectopic expression of Pdx1 in non-beta -cells resulted in the induction of insulin generation (29, 50) or transactivation of insulin promoter activity (40, 51-55). Consistent with previous studies in insulin-producing beta -cells (52, 56), we demonstrated that overexpression of Pdx1 did not increase, but even reduced, the insulin mRNA levels in INS-1-derived subclones. It has been hypothesized that the suppressive effect of Pdx1 in beta -cells is due to cooperative interactions between Pdx1 and other transcription factors (53-57). The present study showed that overexpression of Pdx1 in INS-1 cells also raised the mRNA level of the beta -cell-restricted transcription factor Nkx6.1, known as a potent transcriptional repressor of the intact insulin promoter (22, 25). The negative feedback mechanism of Nkx6.1 provides an alternative explanation for the inhibitory effect of Pdx1 in beta -cells.

The relevance of the increase of Nkx6.1 may also explain the paradoxical effect of Pdx1 on glucagon promoter activity. We showed that induction of Pdx1 in INSralpha beta cells dramatically suppressed the glucagon promoter activity and eventually eliminated the expression of glucagon mRNA and protein. In contrast, the ectopic expression of Pdx1 in alpha TC1 cells, predominantly expressing glucagon, did not inhibit glucagon gene transcription.3 Nkx6.1 is expressed in the insulin-producing beta -cell lines, including INS-1-derived subclones, but not in the alpha -cell lines such as alpha TC1 cells (21, 25). It is therefore likely that Nkx6.1, induced by Pdx1 (17, 25, and the present study), may indeed function as a potent transcriptional repressor (22) and contribute to the inhibitory effect of Pdx1 on glucagon gene transcription. However, this hypothesis cannot explain why targeted disruption of mouse Nkx6.1 gene did not cause increased alpha -cell mass (16). Although we found that Pdx1 is capable of binding the glucagon G1 element, the binding activity is not required for the suppressive function of Pdx1 on the glucagon promoter.3 Protein-protein interactions with other transcription factors including Pax6 could also contribute to the transcriptional repression of glucagon.3 Pax4, a transcriptional repressor of the glucagon promoter (23, 24), is essential for beta /delta -cell development (15) and is expressed transiently in the differentiating fetal beta -cells but not in the differentiated adult beta -cells (25). Although we found that Pdx1 alone did not have any significant effect on the Pax4 mRNA expression, we cannot rule out the possibility that Pdx1 suppresses glucagon promoter activity through synergistic interaction with Pax4.

Overexpression of Pdx1 Raises Cellular Insulin Content without Increasing Insulin mRNA Expression-- Another intriguing function of Pdx1 is the increase in cellular insulin content, without affecting insulin mRNA levels. We therefore suggest that Pdx1 may also regulate the biosynthesis of insulin or the formation or maturation of insulin granules.

Pdx1 Is Required for Maintaining Insulin Expression-- The ectopic expression of Pdx1 alone in glucagonoma cells in vitro (29) and in mouse hepatocytes in vivo (50) resulted in induction of insulin production, suggesting that Pdx1 is a master gene in the regulation of insulin expression. We demonstrated here that dominant-negative suppression of Pdx1 function in INS-1 cells caused a drastic reduction, but not complete elimination, of the insulin mRNA expression, insulin immunofluorescence staining, and cellular insulin content. Our results are in agreement with the previous in vivo study of Ahlgren et al. (17), who showed that beta -cell-specific inactivation of the mouse Pdx1 gene resulted in up to 90% reduction in the pancreatic insulin content. We thus conclude that Pdx1 is required for maintaining insulin expression.

Loss of Pdx1 Function rather than Expression of Brain4 Is the Prerequisite for alpha -Cell Differentiation-- The absence of Pdx1 and the specific expression of brain4 are the hallmarks of differentiated alpha -cells. The present study provided profound evidence that loss of Pdx1 function rather than expression of brain4 is the determining factor for alpha -cell differentiation. We showed that induction of DN-Pdx1 in INSralpha beta and INSrbeta cells not only markedly repressed insulin expression but also caused pronounced expression of glucagon. We also performed immunofluorescence double labeling to show that dominant-negative suppression of Pdx1 function converted the insulin-producing beta -cell lineage to the alpha -cell-dominated phenotype. In contrast, induction of brain4 in INSrbeta cells initiated only detectable amounts of glucagon, without inhibiting the beta -cell-specific gene pattern. The expression of endogenous brain4 in INSralpha beta cells may partially explain the glucagon production.

The beta -cell-specific disruption of Pdx1 in vivo shifted the beta /alpha cell ratio from 5:1 to 1:1 (17), which seems moderate in comparison to the 90% conversion of beta -cells to alpha -cells in our study. The discrepancy may be due to the slower proliferation and neogenesis or to less differentiation plasticity of islet beta -cells in vivo.

Pdx1-specific Patterns of Gene Expression-- We found that the beta -cell genes encoding insulin, IAPP, Glut2, and Nkx6.1 are Pdx1-specific target genes. Dominant-negative suppression of Pdx1 function drastically and selectively reduced the expression of these mRNA species. Although it has been reported that Pdx1 binds to the Pax4 promoter (26), we showed that Pdx1 alone is not sufficient to regulate Pax4 mRNA expression. Glucokinase expression is not restricted to islet beta -cells although it is less abundant in alpha -cells (58). We demonstrated that the mRNA expression of glucokinase is completely unresponsive to Pdx1 regulation. This concurs with a previous study on transgenic mice (17). These results contrast with the earlier claims that Pdx1 regulates the glucokinase gene (46).

Conclusion-- We conclude that Pdx1 is required for maintaining the expression of beta -cell-specific genes and beta -cell lineage differentiation. Loss of Pdx1 function rather than expression of brain4 is the prerequisite for alpha -cell differentiation.

    ACKNOWLEDGEMENTS

We are grateful to D. Cornut-Harry, Y. Dupre, G. Chaffard, C. Bartley, and E.-J. Sarret for expert technical assistance. We are indebted to Drs. P. B. Iynedjian (glucokinase cDNA and INS-r3 and -r9 cells), E. Edlund (Pdx1 cDNA and antibody), S. Saule (Pax6 cDNA), M. S. German (Cdx-2/3 cDNA), B. Thorens (GLUT-2 cDNA), H. Bujard (PUHD 10-3 vector), and N. Quintrell (pTKhygro plasmid). We also thank Dr. S. Seino for kindly providing the MIN6-m9 clone.

    FOOTNOTES

* This work was supported by Swiss National Science Foundation Grant Number 32-49755.96, the Institute for Human Genetics and Biochemistry, the Berger Foundation, the Carlos and Elsie de Reuters Foundation, and the Juvenile Diabetes Foundation International, New York.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence may be addressed: Division de Biochimie Clinique et de Diabétologie Expérimentale, Départment de Médecine Interne, Center Médical Universitaire, CH-1211 Geneva 4, Switzerland. Tel.: 41 22 702 5548; Fax: 41 22 702 5543; E-mail: Haiyan. Wang@medicine.unige.ch or Claes.Wollheim@medicine.unige.ch.

Published, JBC Papers in Press, April 17, 2001, DOI 10.1074/jbc.M101233200

2 H. Wang and C. B. Wollheim, unpublished data.

3 B. Ritz-Laser, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: DN, dominant-negative; rtTA, reverse tetracycline-dependent transactivator; PCR, polymerase chain reaction; EMSA, electrophoretic mobility shift assay; IAPP, islet amyloid polypeptide; DOX, doxycycline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Orci, L. (1982) Diabetes 31, 538-565
2. Apelqvist, A., Li, H., Sommer, L., Beatus, P., Anderson, D. J., Honjo, T., Hrabe de Angelis, M., Lendahl, U., and Edlund, H. (1999) Nature 400, 877-881
3. Gradwohl, G., Dierich, A., LeMeur, M., and Guillemot, F. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 1607-1611
4. Herrera, P. L. (2000) Development 127, 2317-2322
5. Jensen, J., Heller, R. S., Nielsen, T. F., Pedersen, E. E., Lindsell, C., Weinmaster, G., Madsen, O. D., and Serup, P. (2000) Diabetes 49, 163-176
6. Schwitzgebel, V. M., Scheel, D. W., Conners, J. R., Kalamaras, J., Lee, J. E., Anderson, D. J., Sussel, L., Johnson, J. D., and German, M. S. (2000) Development 127, 3533-3542
7. Jonsson, J., Carlsson, L., and Edlund, H. (1994) Nature 371, 606-609
8. Offield, M. F., Jetton, T. L., Labosky, P. A., Ray, M., Stein, R., Magnuson, M. A., Hogan, B. L. M., and Wright, C. V. E. (1996) Development 122, 983-995
9. Stoffers, D. A., Zinkin, N. T., Stanojevic, V., Clarke, W. L., and Habener, J. F. (1997) Nat. Genet. 15, 106-110
10. Naya, F. J., Huang, H. P., Qui, Y., Mutoh, H., DeMayo, F. J., Leiter, A. B., and Tsai, M. J. (1997) Genes Dev. 11, 2323-2334
11. Ahlgren, U., Pfaff, S. L., Jessell, T. M., Edlund, T., and Edlund, H. (1997) Nature 385, 257-260
12. Sussel, L., Kalamaras, J., Hartigan-O'Connor, D. J., Meneses, J. J., Pedersen, R. A., Rubenstein, J. L., and German, M. S. (1998) Development 125, 2213-2221
13. Sander, M., Neubuser, A., Kalamaras, J., Ee, H. C., Martin, G. R., and German, M. S. (1997) Genes Dev. 11, 1662-1673
14. St-Onge, L., Sosa-Pineda, B., Chowdhury, K., Mansouri, A., and Gruss, P. (1997) Nature 387, 406-409
15. Sosa-Pineda, B., Chowdhury, K., Torres, M., Oliver, G., and Gruss, P. (1997) Nature 386, 399-402
16. Sander, M., Sussel, L., Conners, J., Scheel, D., Kalamaras, J., Dela Cruz, F., Schwitzgebel, V., Hayes-Jordan, A., and German, M. (2000) Development 127, 5533-5540
17. Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., and Edlund, H. (1998) Genes Dev. 12, 1763-1768
18. Hussain, M. A., Lee, J., Miller, C. P., and Habener, J. F. (1997) Mol. Cell. Biol. 17, 7186-7194
19. Larsson, L. I., Madsen, O. D., Serup, P., Jonsson, J., and Edlund, H. (1996) Mech. Dev. 60, 175-184
20. Serup, P., Petersen, H. V., Pedersen, E. E., Edlund, H., Leonard, J., Petersen, J. S., Larsson, L. I., and Madsen, O. D. (1995) Biochem. J. 310, 997-1003
21. Jensen, J., Serup, P., Karlsen, C., Nielsen, T. F., and Madsen, O. D. (1996) J. Biol. Chem. 271, 18749-18758
22. Mirmira, R. G., Watada, H., and German, M. S. (2000) J. Biol. Chem. 275, 14743-14751
23. Fujitani, Y., Kajimoto, Y., Yasuda, T., Matsuoka, T.-A., Kaneto, H., Umayahara, Y., Fujita, N., Watada, H., Miyazaki, J.-I., Yamasaki, Y., and Hori, M. (1999) Mol. Cell. Biol. 19, 8281-8291
24. Smith, S. B., Ee, H. C., Conners, J. R., and German, M. S. (1999) Mol. Cell. Biol. 19, 8272-8280
25. Watada, H., Mirmira, R. G., Leung, J., and German, M. S. (2000) J. Biol. Chem. 275, 34224-34230
26. Smith, S. B., Watada, H., Scheel, D. W., Mrejen, C., and German, M. S. (2000) J. Biol. Chem. 275, 36910-36919
27. Madsen, O. D., Andersen, L. C., Michelsen, B., Owerback, D., Larsson, L.-I., Lernmark, A., and Steiner, D. F. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 6652-6656
28. Madsen, O. D., Karlsen, C., Nielsen, E., Lund, K., Kofod, H., Welinder, B., Rehfeld, J. F., Larsson, L.-I., Steiner, D. F., Holst, J. J., and Michelsen, B. K. (1993) Endocrinology 133, 2022-2030
29. Serup, P., Jensen, J., Andersen, F., Jorgensen, M. C., Blume, N., Holst, J. J., and Madsen, O. D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9015-9020
30. Wang, H., Maechler, P., Antinozzi, P. A., Hagenfeldt, K. A., and Wollheim, C. B. (2000) J. Biol. Chem. 17, 35953-35959
31. Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., and Bujard, H. (1995) Science 268, 1766-1769
32. Wang, H., and Iynedjian, P. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4372-4377
33. Trimble, E. R., Halban, P. A., Wollheim, C. B., and Renold, A. E. (1982) J. Clin. Invest. 69, 405-413
34. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1988) EMBO J. 7, 4221-4229
35. German, M. S., Moss, L. G., Wang, J., and Rutter, W. J. (1992) Mol. Cell. Biol. 12, 1777-1788
36. German, M. S., Wang, J., Chadwick, R. B., and Rutter, W. J. (1992) Genes Dev. 6, 2165-2176
37. Ritz-Laser, B., Estreicher, A., Klages, N., Saule, S., and Philippe, J. (1999) J. Biol. Chem. 274, 4124-4132
38. Wang, H., Antinozzi, P. A., Hagenfeldt, K. A., Maechler, P., and Wollheim, C. B. (2000) EMBO J. 19, 4257-4264
39. Wang, H., Maechler, P., Hagenfeldt, K. A., and Wollheim, C. B. (1998) EMBO J. 17, 6701-6713
40. Peshavaria, M., Henderson, E., Sharma, A., Wright, C. V. E., and Stein, R. (1997) Mol. Cell. Biol. 17, 3987-3996
41. Macfarlane, W. M., McKinnon, C. M., Felton-Edkins, Z. A., Cragg, H., James, R. F. L., and Docherty, K. (1999) J. Biol. Chem. 274, 1011-1016
42. Rafiq, I., da Silva Xavier, G., Hooper, S., and Rutter, G. A. (2000) J. Biol. Chem. 275, 15977-15984
43. Rafiq, I., Kennedy, H. J., and Rutter, G. A. (1998) J. Biol. Chem. 273, 23241-23247
44. Minami, K., Yano, H., Miki, T., Nagashima, K., Wang, C.-Z., Tanaka, H., Miyazaki, J.-I., and Seino, S. (2000) Am. J. Physiol. 279, E773-E781
45. Hessabi, B., Ziegler, P., Schmidt, I., Hessabi, C., and Walther, R. (1999) Eur. J. Biochem. 263, 170-177
46. Watada, H., Kajimoto, Y., Umayahara, Y., Matzuoka, T., Kaneto, H., Fujitani, Y., Kamada, T., Kawamori, R., and Yamasaki, Y. (1996) Diabetes 45, 1478-1488
47. Shen, C.-N., Slack, J. M. W., and Tosh, D. (2000) Nat. Cell Biol. 2, 879-887
48. Krapp, A., Knofler, M., Frutiger, S., Hughes, G. J., Hagenbuchle, O., and Wellauer, P. K. (1996) EMBO J. 15, 4317-4329
49. Edlund, H. (1998) Diabetes 47, 1817-1823
50. Ferber, S., Halkin, A., Cohen, H., Ber, I., Einav, V., Goldberg, I., Barshack, I., Seijffers, R., Kopolovic, J., Kaiser, N., and Karasik, A. (2000) Nat. Med. 6, 568-572
51. Glick, E., Leshkowitz, D., and Walker, M. D. (2000) J. Biol. Chem. 275, 2199-2204
52. Marshak, S., Totary, H., Cerasi, E., and Melloul, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15057-15062
53. Marshak, S., Benshushan, E., Shoshkes, M., Havin, L., Cerasi, E., and Melloul, D. (2000) Mol. Cell. Biol. 20, 7583-7590
54. Ohneda, K., Mirmira, R. G., Wang, J., Johnson, J. D., and German, M. S. (2000) Mol. Cell. Biol. 20, 900-911
55. Petersen, H. V., Serup, P., Leodard, J., Michelsen, B. K., and Madsen, O. D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10465-10469
56. Seijffers, R., Ben-David, O., Cohen, Y., Karasik, A., Berezin, M., Newgard, C. B., and Ferber, S. (1999) Endocrinology 140, 3311-3317
57. Peers, B., Leonard, J., Sharma, S., Teitelman, G., and Montminy, M. R. (1994) Mol. Endocrinol. 8, 1798-1806
58. Heimberg, H., De Vos, A., Moens, K., Quartier, E., Bouwens, L., Pipeleers, D., Van Schaftingen, E., Madsen, O., and Schuit, F. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7036-7041


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J EndocrinolHome page
T. Jin
Mechanisms underlying proglucagon gene expression
J. Endocrinol., July 1, 2008; 198(1): 17 - 28.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Sun, L. Zhang, H. F. Gu, W. Han, M. Ren, F. Wang, B. Gong, L. Wang, H. Guo, W. Xin, et al.
Peroxisome Proliferator-Activated Receptor-{alpha} Regulates the Expression of Pancreatic/Duodenal Homeobox-1 in Rat Insulinoma (INS-1) Cells and Ameliorates Glucose-Induced Insulin Secretion Impaired by Palmitate
Endocrinology, February 1, 2008; 149(2): 662 - 671.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Gosmain, I. Avril, A. Mamin, and J. Philippe
Pax-6 and c-Maf Functionally Interact with the {alpha}-Cell-specific DNA Element G1 in Vivo to Promote Glucagon Gene Expression
J. Biol. Chem., November 30, 2007; 282(48): 35024 - 35034.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. M. Keller, S. McWeeney, A. Arsenlis, J. Drouin, C. V. E. Wright, H. Wang, C. B. Wollheim, P. White, K. H. Kaestner, and R. H. Goodman
Characterization of Pancreatic Transcription Factor Pdx-1 Binding Sites Using Promoter Microarray and Serial Analysis of Chromatin Occupancy
J. Biol. Chem., November 2, 2007; 282(44): 32084 - 32092.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. Gromada, I. Franklin, and C. B. Wollheim
{alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Endocr. Rev., February 1, 2007; 28(1): 84 - 116.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. E Cerf
Transcription factors regulating {beta}-cell function.
Eur. J. Endocrinol., November 1, 2006; 155(5): 671 - 679.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Wang, T. Liu, Z. Li, X. Ma, and T. Jin
Redundant and Synergistic Effect of Cdx-2 and Brn-4 on Regulating Proglucagon Gene Expression
Endocrinology, April 1, 2006; 147(4): 1950 - 1958.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
E N Fazio, M Everest, R Colman, R Wang, and C L Pin
Altered Glut-2 accumulation and {beta}-cell function in mice lacking the exocrine-specific transcription factor, Mist1
J. Endocrinol., December 1, 2005; 187(3): 407 - 418.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
M. L.M. Khoo, L. R. McQuade, M. S.R. Smith, J. G. Lees, K. S. Sidhu, and B. E. Tuch
Growth and Differentiation of Embryoid Bodies Derived from Human Embryonic Stem Cells: Effect of Glucose and Basic Fibroblast Growth Factor
Biol Reprod, December 1, 2005; 73(6): 1147 - 1156.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. M. Holland, L. J. Gonez, G. Naselli, R. J. MacDonald, and L. C. Harrison
Conditional Expression Demonstrates the Role of the Homeodomain Transcription Factor Pdx1 in Maintenance and Regeneration of {beta}-Cells in the Adult Pancreas
Diabetes, September 1, 2005; 54(9): 2586 - 2595.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
H. Wang, G. Kouri, and C. B. Wollheim
ER stress and SREBP-1 activation are implicated in {beta}-cell glucolipotoxicity
J. Cell Sci., September 1, 2005; 118(17): 3905 - 3915.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. C. Schisler, P. B. Jensen, D. G. Taylor, T. C. Becker, F. K. Knop, S. Takekawa, M. German, G. C. Weir, D. Lu, R. G. Mirmira, et al.
The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells
PNAS, May 17, 2005; 102(20): 7297 - 7302.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. F. Pino, D. Z. Ye, K. D. Linning, C. D. Green, B. Wicksteed, V. Poitout, and L. K. Olson
Elevated Glucose Attenuates Human Insulin Gene Promoter Activity in INS-1 Pancreatic {beta}-Cells via Reduced Nuclear Factor Binding to the A5/Core and Z Element
Mol. Endocrinol., May 1, 2005; 19(5): 1343 - 1360.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Iype, J. Francis, J. C. Garmey, J. C. Schisler, R. Nesher, G. C. Weir, T. C. Becker, C. B. Newgard, S. C. Griffen, and R. G. Mirmira
Mechanism of insulin Gene Regulation by the Pancreatic Transcription Factor Pdx-1: APPLICATION OF PRE-mRNA ANALYSIS AND CHROMATIN IMMUNOPRECIPITATION TO ASSESS FORMATION OF FUNCTIONAL TRANSCRIPTIONAL COMPLEXES
J. Biol. Chem., April 29, 2005; 280(17): 16798 - 16807.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
H. Kaneto, Y. Nakatani, T. Miyatsuka, T.-a. Matsuoka, M. Matsuhisa, M. Hori, and Y. Yamasaki
PDX-1/VP16 Fusion Protein, Together With NeuroD or Ngn3, Markedly Induces Insulin Gene Transcription and Ameliorates Glucose Tolerance
Diabetes, April 1, 2005; 54(4): 1009 - 1022.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Y. Li, X. Cao, L.-X. Li, P. L. Brubaker, H. Edlund, and D. J. Drucker
{beta}-Cell Pdx1 Expression Is Essential for the Glucoregulatory, Proliferative, and Cytoprotective Actions of Glucagon-Like Peptide-1
Diabetes, February 1, 2005; 54(2): 482 - 491.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Flock, X. Cao, and D. J. Drucker
Pdx-1 Is Not Sufficient for Repression of Proglucagon Gene Transcription in Islet or Enteroendocrine Cells
Endocrinology, January 1, 2005; 146(1): 441 - 449.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
H. Thomas, S. Senkel, S. Erdmann, T. Arndt, G. Turan, L. Klein-Hitpass, and G. U. Ryffel
Pattern of genes influenced by conditional expression of the transcription factors HNF6, HNF4{alpha} and HNF1{beta} in a pancreatic {beta}-cell line
Nucleic Acids Res., November 1, 2004; 32(19): e150 - e150.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. R. Gauthier, T. Brun, E. J. Sarret, H. Ishihara, O. Schaad, P. Descombes, and C. B. Wollheim
Oligonucleotide Microarray Analysis Reveals PDX1 as an Essential Regulator of Mitochondrial Metabolism in Rat Islets
J. Biol. Chem., July 23, 2004; 279(30): 31121 - 31130.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
T. Iype, D. G. Taylor, S. M. Ziesmann, J. C. Garmey, H. Watada, and R. G. Mirmira
The Transcriptional Repressor Nkx6.1 Also Functions as a Deoxyribonucleic Acid Context-Dependent Transcriptional Activator during Pancreatic {beta}-Cell Differentiation: Evidence for Feedback Activation of the nkx6.1 Gene by Nkx6.1
Mol. Endocrinol., June 1, 2004; 18(6): 1363 - 1375.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. Liberzon, G. Ridner, and M. D. Walker
Role of intrinsic DNA binding specificity in defining target genes of the mammalian transcription factor PDX1
Nucleic Acids Res., January 2, 2004; 32(1): 54 - 64.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Suzuki, K. Tobe, Y. Terauchi, K. Komeda, N. Kubota, K. Eto, T. Yamauchi, K. Azuma, H. Kaneto, T. Taguchi, et al.
Pdx1 Expression in Irs2-deficient Mouse {beta}-Cells Is Regulated in a Strain-dependent Manner
J. Biol. Chem., October 31, 2003; 278(44): 43691 - 43698.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Vincent, Y. Guz, M. Rozenberg, G. Webb, M. Furuta, D. Steiner, and G. Teitelman
Abrogation of Protein Convertase 2 Activity Results in Delayed Islet Cell Differentiation and Maturation, Increased {alpha}-Cell Proliferation, and Islet Neogenesis
Endocrinology, September 1, 2003; 144(9): 4061 - 4069.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Ber, K. Shternhall, S. Perl, Z. Ohanuna, I. Goldberg, I. Barshack, L. Benvenisti-Zarum, I. Meivar-Levy, and S. Ferber
Functional, Persistent, and Extended Liver to Pancreas Transdifferentiation
J. Biol. Chem., August 22, 2003; 278(34): 31950 - 31957.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Wang, P. Maechler, P. A. Antinozzi, L. Herrero, K. A. Hagenfeldt-Johansson, A. Bjorklund, and C. B. Wollheim
The Transcription Factor SREBP-1c Is Instrumental in the Development of beta -Cell Dysfunction
J. Biol. Chem., May 2, 2003; 278(19): 16622 - 16629.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
X. Cao, G. Flock, C. Choi, D. M. Irwin, and D. J. Drucker
Aberrant Regulation of Human Intestinal Proglucagon Gene Expression in the NCI-H716 Cell Line
Endocrinology, May 1, 2003; 144(5): 2025 - 2033.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
H. Wang, K. Hagenfeldt-Johansson, L. A. Otten, B. R. Gauthier, P. L. Herrera, and C. B. Wollheim
Experimental Models of Transcription Factor-Associated Maturity-Onset Diabetes of the Young
Diabetes, December 1, 2002; 51(90003): S333 - 342.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
G. Flock and D. J. Drucker
Pax-2 Activates the Proglucagon Gene Promoter But Is Not Essential for Proglucagon Gene Expression or Development of Proglucagon-Producing Cell Lineages in the Murine Pancreas or Intestine
Mol. Endocrinol., October 1, 2002; 16(10): 2349 - 2359.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Wang and C. B. Wollheim
ChREBP Rather than USF2 Regulates Glucose Stimulation of Endogenous L-pyruvate Kinase Expression in Insulin-secreting Cells
J. Biol. Chem., August 30, 2002; 277(36): 32746 - 32752.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Kaneto, G. Xu, N. Fujii, S. Kim, S. Bonner-Weir, and G. C. Weir
Involvement of c-Jun N-terminal Kinase in Oxidative Stress-mediated Suppression of Insulin Gene Expression
J. Biol. Chem., August 9, 2002; 277(33): 30010 - 30018.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
E. J. Abraham, C. A. Leech, J. C. Lin, H. Zulewski, and J. F. Habener
Insulinotropic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing Cells
Endocrinology, August 1, 2002; 143(8): 3152 - 3161.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Wang, B. R. Gauthier, K. A. Hagenfeldt-Johansson, M. Iezzi, and C. B. Wollheim
Foxa2 (HNF3beta ) Controls Multiple Genes Implicated in Metabolism-Secretion Coupling of Glucose-induced Insulin Release
J. Biol. Chem., May 10, 2002; 277(20): 17564 - 17570.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Hussain, C. P. Miller, and J. F. Habener
Brn-4 Transcription Factor Expression Targeted to the Early Developing Mouse Pancreas Induces Ectopic Glucagon Gene Expression in Insulin-producing beta Cells
J. Biol. Chem., May 3, 2002; 277(18): 16028 - 16032.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Kaneto, A. Sharma, K. Suzuma, D. R. Laybutt, G. Xu, S. Bonner-Weir, and G. C. Weir
Induction of c-Myc Expression Suppresses Insulin Gene Transcription by Inhibiting NeuroD/BETA2-mediated Transcriptional Activation
J. Biol. Chem., April 5, 2002; 277(15): 12998 - 13006.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. K. Chakrabarti, J. C. James, and R. G. Mirmira
Quantitative Assessment of Gene Targeting in Vitro and in Vivo by the Pancreatic Transcription Factor, Pdx1. IMPORTANCE OF CHROMATIN STRUCTURE IN DIRECTING PROMOTER BINDING
J. Biol. Chem., April 5, 2002; 277(15): 13286 - 13293.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/27/25279    most recent
M101233200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, H.
Right arrow Articles by Wollheim, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, H.
Right arrow Articles by Wollheim, C. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement